Protein-Bound Uremic Retention Solutes in Long Nocturnal Hemodialysis
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Dec 28, 2006
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • Maintenance hemodialysis (\> 3 months duration)
- • Informed consent
- Exclusion Criteria:
- • No consent
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clayton, Victoria, Australia
Geelong, Victoria, Australia
Hasselt, Limburg, Belgium
Leuven, Vlaams Brabant, Belgium
Patients applied
Trial Officials
Björn KI Meijers, MD
Principal Investigator
Universitaire Ziekenhuizen KU Leuven
Pieter Evenepoel, MD, PhD
Study Director
Universitaire Ziekenhuizen KU Leuven
Tom Dejagere, MD
Principal Investigator
Virga Jesse Ziekenhuis
Nigel Toussaint, MD
Principal Investigator
Geelong Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials